文献速递糖尿病

2型糖尿病的药物基因组学:精准医学还是发现工具?

Pharmacogenetics in type 2 diabetes: precision medicine or discovery tool?
PubMed 文献 · Diabetologia · 2017-03-10

本文为观点性综述,回顾2型糖尿病药物基因组学领域,聚焦磺脲类药物和二甲双胍,讨论药物基因组学的主要用途、转化障碍及未来方向。作者指出遗传变异对药物反应的影响可能强于对疾病发病的影响,但将其转化为临床实践仍面临诸多障碍。

要点

  • 药物基因组学可用于识别新药靶点、阐明病理生理、揭示疾病异质性及辅助精准治疗。
  • 单基因糖尿病(如MODY或新生儿糖尿病)已有药物基因组学成功应用的先例。
  • 磺脲类药物和二甲双胍是本文重点讨论的2型糖尿病药物基因组学对象。

核心结论

  • 药物基因组学发现可能有助于识别新药靶点、阐明病理生理、揭示疾病异质性、帮助优先排序遗传关联区域中的特定基因,并促进个体化或精准治疗。
  • 单基因糖尿病亚型(如MODY或新生儿糖尿病)已有药物基因组学概念成功应用的先例,但更常见的2型糖尿病是否也能获得类似洞见仍有待观察。
  • 随着遗传学方法的进步,候选基因、大规模基因分型和全基因组关联研究的逐步应用已开始产生可能改变临床实践的有提示性结果,但将糖尿病药物基因组学发现转化为临床仍存在许多障碍。

研究设计与样本

  • 本文为观点性综述,对2型糖尿病药物基因组学领域进行当代概览,聚焦磺脲类药物和二甲双胍。

主要发现

  • 遗传变异对药物反应的影响可能强于通常见到的对疾病发病的影响。
  • 遗传变异改善疾病结局预测的能力在标准临床风险因素之外仍然有限。
  • 候选基因、大规模基因分型和全基因组关联研究的逐步应用已开始产生有提示性的结果。

局限性

  • 遗传变异在标准临床风险因素之外改善疾病结局预测的能力有限。
  • 将糖尿病药物基因组学发现转化为临床仍存在许多障碍。
  • 更常见的2型糖尿病是否能获得与单基因糖尿病亚型类似的药物基因组学洞见仍有待观察。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In recent years, technological and analytical advances have led to an explosion in the discovery of genetic loci associated with type 2 diabetes. However, their ability to improve prediction of disease outcomes beyond standard clinical risk factors has been limited. On the other hand, genetic effects on drug response may be stronger than those commonly seen for disease incidence. Pharmacogenetic findings may aid in identifying new drug targets, elucidate pathophysiology, unravel disease heterogeneity, help prioritise specific genes in regions of genetic association, and contribute to personalised or precision treatment. In diabetes, precedent for the successful application of pharmacogenetic concepts exists in its monogenic subtypes, such as MODY or neonatal diabetes. Whether similar insights will emerge for the much more common entity of type 2 diabetes remains to be seen. As genetic approaches advance, the progressive deployment of candidate gene, large-scale genotyping and genome-wide association studies has begun to produce suggestive results that may transform clinical practice. However, many barriers to the translation of diabetes pharmacogenetic discoveries to the clinic still remain. This perspective offers a contemporary overview of the field with a focus on sulfonylureas and metformin, identifies the major uses of pharmacogenetics, and highlights potential limitations and future directions.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Florez JC. Pharmacogenetics in type 2 diabetes: precision medicine or discovery tool? Diabetologia. 2017. PMID: 28283684. doi:10.1007/s00125-017-4227-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。